Factors Contributing to Readmission of Heart Failure Patients to Emergency Departments and Prospects for Improvement (CARDIO-REA)

January 27, 2026 updated by: Centre Hospitalier Régional Metz-Thionville

Heart failure (HF) represents a major public health challenge due to its increasing prevalence and significant impact on healthcare systems.

The burden of frequent readmissions leads to increased healthcare costs, deterioration in the quality of care, and reduced availability of hospital resources for new patients. It is therefore essential to optimize the management of patients with heart failure from their first visit to the emergency department in order to improve their prognosis and reduce the risk of rehospitalization.

In this context, this study aims to identify the key factors associated with early readmissions (< 30 days) and to propose strategies to improve patient management and follow-up after discharge from hospital.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

58

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Metz, France, 57085
        • CHR Metz-Thionville

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Adult patients hospitalized for acute heart failure over a period of 6 months.

Description

Inclusion Criteria:

  • Patients aged 18 years or older, admitted to the emergency department for confirmed acute heart failure. Hospitalization following admission to the emergency department, with at least one documented post-hospitalization follow-up visit.

Exclusion Criteria:

  • Patients under the age of 18 with a primary diagnosis unrelated to heart failure after analysis of their medical records. Patients in palliative care receiving only comfort treatment. No documented post-hospitalization follow-up. Patients who object to the use of their medical data for research purposes.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Key factors determining the rehospitalization
Time Frame: 6 months
Key factors determining the rehospitalization of patients with heart failure
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Centre Hospitalier Régional Metz-Thionville

Investigators

  • Principal Investigator: Laure ABENSUR VUILLAUME, CHR Metz Thionville Hopital de Mercy

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2025

Primary Completion (Actual)

June 30, 2025

Study Completion (Actual)

June 30, 2025

Study Registration Dates

First Submitted

January 27, 2026

First Submitted That Met QC Criteria

January 27, 2026

First Posted (Actual)

February 4, 2026

Study Record Updates

Last Update Posted (Actual)

February 4, 2026

Last Update Submitted That Met QC Criteria

January 27, 2026

Last Verified

December 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2025-04-Obs-CHRMT

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Heart Failure

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe